Chemophototherapy with Porphyrin-phospholipid Liposomes Permeabilized by Red Light
Chemophototherapy with Porphyrin-phospholipid Liposomes Permeabilized by Red Light
批准号:
10190938
负责人:
Jonathan F Lovell
金额:
$49.29万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-15 至 2023-05-31
关键词:
AblationAddressAmericanBloodBlood CirculationBlood VesselsCancer ModelCarotid ArteriesCellsClinicalClinical ResearchClinical TrialsCollagenComputer AssistedDepositionDevelopmentDiagnosisDiffuseDiseaseDisease modelDoseDoxorubicinDrug Delivery SystemsDrug KineticsDrug ModelingsElementsEndocrineEnvironmentExcisionExposure toFailureFeathersFiberFormulationGenetically Engineered MouseGoalsHourImageLaparoscopyLasersLightLipidsLiposomal DoxorubicinLiposomesMalignant neoplasm of pancreasMeasurementMediatingMembraneMetastatic Pancreatic AdenocarcinomaMethodologyModalityModelingMolecularMorphologyMotivationMusNatureNeoplasm MetastasisOperative Surgical ProceduresOxygenPUVA PhotochemotherapyPainPatientsPerfusionPeroxidesPharmaceutical PreparationsPhospholipidsPhototherapyPhysiologicalPorphyrinsPrimary NeoplasmPrognosisPropertyRadiation therapyRattusReportingRodentSaphenous VeinScanningSerumSheepSideSphingomyelinsStructureSurvival RateSymptomsTechniquesTimeToxic effectUnsaturated FatsVeinsWorkablative procedureadvanced diseaseanti-cancerbasecancer diagnosiscancer typechemotherapyclinically relevantcomputerized toolsconventional therapyin vivointerstitialirinotecanlight dosimetryminimally invasivemouse modelnoveloptical fiberpalliationpancreatic cancer modelpancreatic cancer patientspancreatic neoplasmpatient derived xenograft modelporphyrin aresponsetheranosticstreatment planningtumortumor ablationtumor eradication
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Pancreatic cancer (PaCa) has the poorest prognosis amongst all major cancer types and claimed the
lives of over 41,000 Americans in 2016. Upon clinical presentation, most patients are diagnosed with
locally advanced disease without good treatment options, either to delay progression or for palliation.
Chemotherapy is generally ineffective due to hypovascular nature of the tumor. Tumor removal is
often unfeasible due to the proximity of major blood vessels, which also complicate thermal ablative
procedures. We seek to develop chemophototherapy as a novel ablative modality for PaCa. This
approach combines phototherapy and chemotherapy using a single agent, based on light-activated
liposomes. Recently, long-circulating liposomal irinotecan (IRI) was approved for treating PaCa. We
have found that when small amounts of porphyrin-phospholipid (i.e. 2 molar percent) are incorporated
into conventional stealth liposomes, stability and long blood-circulating properties are retained. In prior
work using doxorubicin, circulation was >25 hours in rodents, but the liposomes rapidly release their
contents (in a couple of minutes) upon exposure to clinically relevant red light. This results in an order
of magnitude greater drug deposition in the tumor, leading to potent ablation. We will adapt this
approach to develop a long-circulating, light-activated form of irinotecan. We will also apply recent
methodology to develop and assess an ultrafast light-triggered release version, by incorporating small
amounts of unsaturated lipids, together with the PoP. We will assess the IRI PoP formulations in
patient derived xenografts that mimic feathers of the clinical disease, as well as in an orthotopic model
derived from a genetically engineered mouse model of the disease. Treatment parameters such as
the drug dose, light dose, and drug-light interval will be assessed. We will develop and assess
interstitial phototreatment and computer-aided treatment planning of optical fiber placement, based on
MR scans with light propagation modeling that will be required to apply chemophototherapy in clinical
studies. We will characterize the depth of ablation measurements and treatment with multiple
interstitial fibers in large rat tumors. Finally, in order to asses the applicability of this technique near
the critical vessels found in many PaCa tumors, we will characterize drug and light dose functional
responses in large veins in rodents in vivo, in sheep carotid arteries ex vivo and in acellular collagen
vessels.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/wnan.1315
发表时间:
2015-03
期刊:
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
影响因子:
8.6
作者:
[Luo, Dandan, Carter, Kevin A., Lovell, Jonathan F.]
通讯作者:
Lovell, Jonathan F.
DOI:
10.1002/wnan.1420
发表时间:
2017-01
期刊:
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
影响因子:
8.6
作者:
[Zhang, Yumiao, Lovell, Jonathan F.]
通讯作者:
Lovell, Jonathan F.
DOI:
10.7150/thno.15701
发表时间:
2016
期刊:
Theranostics
影响因子:
12.4
作者:
[Carter KA, Luo D, Razi A, Geng J, Shao S, Ortega J, Lovell JF]
通讯作者:
Lovell JF
DOI:
10.1002/btm2.10032
发表时间:
2016-09
期刊:
Bioengineering & translational medicine
影响因子:
7.4
作者:
[Miranda D, Lovell JF]
通讯作者:
Lovell JF
DOI:
10.3390/molecules23040892
发表时间:
2018-04-12
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
作者:
[Chitgupi U, Lovell JF, Rajendiran V]
通讯作者:
Rajendiran V
共 13 条
Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis
-
批准号:10598146
-
项目类别:
-
资助金额:$45.87万
-
财政年份:2022
-
负责人:Jonathan F Lovell
-
依托单位:
Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis
-
批准号:10441958
-
项目类别:
-
资助金额:$48.09万
-
财政年份:2022
-
负责人:Jonathan F Lovell
-
依托单位:
Light-Triggered Drug Release in Primed Pancreatic Tumors
-
批准号:8562197
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR Light
-
批准号:8737994
-
项目类别:
-
资助金额:$38.86万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR Light
-
批准号:9135540
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR Light
-
批准号:8609764
-
项目类别:
-
资助金额:$38.94万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
Light-Triggered Drug Release in Primed Pancreatic Tumors
-
批准号:9130825
-
项目类别:
-
资助金额:$34.15万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
Light-Triggered Drug Release in Primed Pancreatic Tumors
-
批准号:8717660
-
项目类别:
-
资助金额:$31.69万
-
财政年份:2013
-
负责人:Jonathan F Lovell
-
依托单位:
海外基金